Skip to content
10-Q

Quarterly Report

ENDONOVO THERAPEUTICS, INC. ENDV

0001493152-22-023661

← back to feed
Filed
Aug 22, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2022 · Aug 19, 2022 152.48M sh
Long Term Debt Q2 2022 · Jun 30, 2022 $7.41M
Current Liabilities Q2 2022 · Jun 30, 2022 $20.68M
Current Liabilities Q2 2022 · Dec 31, 2021 $17.7M
Total Liabilities Q2 2022 · Jun 30, 2022 $20.75M
Total Liabilities Q2 2022 · Dec 31, 2021 $17.78M
Current Assets Q2 2022 · Jun 30, 2022 $5.95K
Current Assets Q2 2022 · Dec 31, 2021 $94.86K
Total Assets Q2 2022 · Jun 30, 2022 $1.59M
Total Assets Q2 2022 · Dec 31, 2021 $2.01M
Cash And Equivalents Q2 2022 · Dec 31, 2021 $85.94K
Shares Diluted Q2 2022 · Jun 30, 2021 58.49M sh
Shares Diluted Q2 2022 · Jun 30, 2021 50.08M sh
Operating Cash Flow Q2 2022 · Jun 30, 2021 −$425.88K
Stockholders Equity Q2 2022 · Jun 30, 2021 −$16.98M
Stockholders Equity Q2 2022 · Mar 31, 2021 −$15.97M
Stockholders Equity Q2 2022 · Dec 31, 2020 −$14.37M
Eps Diluted Q2 2022 · Jun 30, 2021 −$0.02
Eps Diluted Q2 2022 · Jun 30, 2021 −$0.08
Eps Basic Q2 2022 · Jun 30, 2021 −$0.02
Eps Basic Q2 2022 · Jun 30, 2021 −$0.08
Net Income Q2 2022 · Jun 30, 2021 −$1.3M
Net Income Q2 2022 · Jun 30, 2021 −$3.98M
Net Income Q2 2022 · Mar 31, 2021 −$2.68M
Operating Income Q2 2022 · Jun 30, 2021 −$570.05K
Operating Income Q2 2022 · Jun 30, 2021 −$1.16M
Gross Profit Q2 2022 · Jun 30, 2021 $29.78K
Gross Profit Q2 2022 · Jun 30, 2021 $61.98K
Cost Of Revenue Q2 2022 · Jun 30, 2021 $500
Cost Of Revenue Q2 2022 · Jun 30, 2021 $3.02K
Revenue Q2 2022 · Jun 30, 2021 $30.28K
Revenue Q2 2022 · Jun 30, 2021 $65K